The Somahlution Team is comprised of individuals with considerable experience in the medical device and pharmaceutical industries, and with demonstrated ability to take product from concept to commercialization. The team works closely with its extensive network of expert advisors and consultants for determining clinical, regulatory and marketing strategies. The team is agile and moves swiftly and efficiently to navigate and adapt to different and changing regulatory and economic landscapes.
At Somahlution, we are serious about surrounding ourselves with intelligent, experienced professionals who can help us grow our business and improve our processes. Strong corporate governance is essential for a successful business, and our board members ensure Somahlution operates with integrity and accountability. We seek to build and maintain a Board of Directors with a wide range of experiences, competencies and perspectives and who help direct strategy, and can help us adapt to growing and changing markets, and geographic and regulatory environments.
Dr. Dhaduk is the Chairman of the Board of Directors of Somahlution. He is an accomplished serial entrepreneur and serves as Chairman of several biotechnology companies, many of which he cofounded, including, Apicore Pharma, Synerex Pharmaceuticals, Nuron Biotech and Core Pharma. Dr. Dhaduk provides leadership and guidance in the areas of product development, marketing, partner relationships, financial matters, and corporate governance. His extensive background in biotechnology and the pharmaceutical industry is an important asset to Somahlution’s development and business plans.
Dr. Dhaduk is an actively practicing neurologist and is currently the Chief of Neurology at the Community Medical Center in Scranton, PA and a Fellow of the American Academy of Neurology. His post-graduate medical training was conducted at the B.J. Medical College in Ahmedabad, India and at the Medical College of Pennsylvania in Philadelphia, where he also served as the Chief Resident in Neurology.
Dr. Dhaduk has received numerous honors in medical practice. Most notably, he received the David Dunn Memorial Award in 1986 and 1987 for Outstanding Teaching and Study of Neurology at the Medical College of Pennsylvania. He also serves on the board of several professional organizations in neurology and medicine. He is the chair of CARITAS International Trading and CARITAS Hospitality, LLC, on the advisory boards of Hope Medical Institute, Lublin College of Medicine, Poland, as well as the Lupus Foundation of Pennsylvania. He has been awarded the National Leadership Award serving as honorary co-chairman of the Physician’s Advisory Board, Pennsylvania.
Dr. Chandran co-founded Somahlution with Chairman Dr. Dhaduk, and has served as the Company’s Chief Executive and a member of the Board of Directors since inception in 2010. He is a distinguished biotechnology veteran with nearly 25 years of leadership positions. Until 2012, Dr. Chandran was the Director of the Center of Excellence for Biopharmaceutical Research & Development and Professor of Pharmaceutics at North Dakota State University. Prior to that, he was the Chief Technology Officer at the BioTx Division of Pfizer, in Cambridge. Previous to Pfizer, he was a Professor at the Institute for Hepatitis and Virus Research in Doylestown, PA, and was the Chief Operating Officer and Chief Scientific Officer at Nucleonics, the first RNAi-based company, in Horsham PA, a company that he cofounded while on the faculty at Thomas Jefferson University’s Biochemistry Department.
Prior to founding Nucleonics, Dr. Chandran led the DNA Vaccine Division of Wyeth-Lederle Vaccines following its 1998 acquisition of Apollon, Inc., a biotech company in Malvern, PA, focused on advancing DNA vaccine-based product candidates for infectious diseases and cancer.
Dr. Chandran received his Ph.D. from Memorial University in Newfoundland, Canada and completed a post-doctoral fellowship at Fox Chase Cancer Center in Philadelphia. He is a strategic consultant and a member of the Board of Directors for several emerging and established biotechnology companies.
Dr. Pachuk joined Somahlution as its Chief Scientific Officer in August 2011 and is a member of the Company’s Board of Directors. She has twenty years of R&D leadership experience in the pharmaceutical and biotech sectors with expertise in drugs, biologics and vaccine development. She was involved in advancing multiple product candidates into the clinic.
Dr. Pachuk began her biotech career with Apollon, Inc. developing oligonucleotide-based therapeutics, and subsequently DNA-based vaccines for both viral and oncology indications. Following the acquisition of Apollon, Inc. by Wyeth-Lederle Vaccines in 1998 she continued to direct vaccine programs which resulted in several products being advanced into the clinic.
In 2001 she co-founded Nucleonics, a biotech focused on the development of RNAi-based therapeutics. Until April of 2008, she was VP of Preclinical Research. Since then and until joining Somahlution, Dr. Pachuk has lead biology efforts for Pfizer’s oligonucleotide therapeutic programs in the areas of oncology and metabolic disease and was a member of the Executive Leadership Team.
Dr. Pachuk received her Ph.D. in molecular virology from the University of Pennsylvania and completed a post-doctoral fellowship at SmithKline Beecham.
We invest a lot of time and effort in finding people with the right mix of experiences, diversity and backgrounds who will work together to make the best decisions for the Company and drive results. We believe in operating our business at the highest ethical standards, and our values of honesty, fairness and objectivity guide our business and ensure we maintain the trust of our constituents.
(See Bio Above)
(See Bio Above)
Dr. Goeken, M.D. serves as Chief Medical Officer of Somahlution. He joined the company in January of 2013 and is a veteran in designing and managing global clinical studies for biologics and devices in various therapeutic areas.
He received his M.D. from St. Christopher’s College of Medicine in the UK, having completed his clinical training at LSU Health Sciences Center in Baton Rouge, Louisiana. Following the completion of his medical training, he joined The Methodist Hospital Research Institute in Houston where he worked as a Medical Research Manager. He then went on to work at Pharm-Olam International, also in Houston, where he was responsible for Medical Affairs and Global Pharmacovigilance, as well as Safety Database Systems, and was involved in global clinical studies.
In 2010 Dr. Goeken moved to Pennsylvania, as Vice President of Clinical and Medical Affairs at Nuron Biotech, responsible for advancing multiple therapeutic international programs through the clinic.
Mr. Cabrera is Vice President of Regulatory Affairs & Quality Affairs and is Somahlution's Management Representative. He joined Somahlution in March of 2014 and has been developing global regulatory affairs strategies and Quality Systems compliant with US FDA and European regulations.
Mr. Cabrera served in the U.S. Army as a Combat Medic with the 101st Airborne Division in Ft. Campbell KY. After graduating from the University of Dallas with a B.A. in Cell Biology in 1994, he went on to teach science courses in high school and college. Since 2001, Jose managed several clinical studies that involved Class III implantable medical devices and prepared two PMA submissions for a Dutch ophthalmology device company entering into the US market.
After receiving FDA approval for the new technology devices, Mr. Cabrera manage international regulatory affairs and act as Quality System liaison for all of Bausch + Lomb’s businesses in Latin America. The portfolio included pharmaceuticals, medical devices and nutritional products. He provided regulatory affairs support for manufacturing facility in Porto Alegre Brazil. He also worked for BIOMET in Palm Beach Gardens as the Global Regulatory Affairs Lead where he was responsible for new product registrations, global surveillance, and medical device reporting. Most recently, Mr. Cabrera worked as a consultant to small and large organizations providing support in authoring clinical, quality and regulatory procedures and policies and supporting ISO 13485 implementation and CE marking of medical devices for Europe.
Ms. Johnson has been with Somahlution since August 2014. She has over 20 years of experience in accounting and finance and 17 years in the medical device industry.
She received her BS degree in Accounting from Florida State University and began her career with Centex Homes in South Florida, holding a position of Assistant Controller.
She then joined Biomet 3i in 1998, where she was responsible for the global financial dental organization with a heavy emphasize on ERP implementation, financial reporting and process improvement.
Mary joined Somahlution in September 2014. She has over 26 years of experience in operations, supply chain and accounting, with the most recent seven years working in the pharma industry.
Mary received an AA Degree in Accounting at Bucks County Community College, Newtown, PA and Continuing Education Credits in Accounting and Information Technology at La Salle University, Philadelphia, PA.
She began her career with Modern Mailers, Inc. as a System’s Analyst and Programmer, designing accounting and supply systems in both Cobol and RPG languages. She successfully implemented the operations and supply chains for the Publishing Industry and Pharmaceutical Industry for companies such as Associates in Medical Marketing, Synerx, Mylan and Apicore.
Ms. Gerard has been with Somahlution since July of 2012. She has over 20 years of experience in management and over 10 years of experience in human resources.
Karen received her A.S. in Science from University of Maine at Presque Isle and attended the University of Southern Maine Nursing Program.
Karen began her career with UNUM, a market leader in making disability, life, accident and critical illness insurance accessible in the workplace, working in the Medical Benefit department for four years and spent six years managing the Life & AD&D Benefit department.
Karen was Loss Mitigation Manager for Morgan Stanley’s Residential Mortgage Business, which was responsible for monitoring vendor performance, mitigating and identifying risk and negotiating with mortgage originators on delinquent loans with counterparties in the U.S.
As the strategic direction of Somahlution is determined and adjusted over time, the Strategic Advisory Board provides advice and guidance as our direction is formulated. Our advisory board members are renowned experts in their fields and top business minds who bring their own unique experience and expertise to Somahlution. These individuals provide invaluable service and key insights for our Company.
Timothy Schroeder, CEO and Founder of CTI, has over 30 years of clinical, academic, and industry experience in leading US and global Phase I through Phase IV drug development programs. Tim oversees CTI’s long-term growth strategy and all operational aspects of the company. He consults with pharmaceutical companies on strategic decisions surrounding clinical and commercial drug development issues, and has served as a reviewer to numerous FDA Advisory Panels, including CDER and CBER. Prior to founding CTI, Tim held numerous faculty positions with the University of Cincinnati, College of Medicine and was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, where he oversaw the development of biological agents, generic drugs, diagnostics, preservation solutions, and therapeutic agents for use in the transplant field. Tim is currently a board member for over a dozen corporate and non-profit organizations. Tim received his Master of Science in Environmental Health Sciences from the University of Cincinnati and his Bachelor of Science in Natural Sciences from Xavier University.
David Taggart is currently Professor of Cardiovascular Surgery at the University of Oxford.
He qualified from Glasgow University in 1981 and in 1989 was awarded an M.D. with Honours for studies on the effects of hypothermia on the metabolic response to cardiac surgery. He subsequently trained as the Senior Registrar at the Royal Brompton Hospital under Professor Yacoub and Mr. Lincoln.
In 1995 he was appointed consultant cardiac surgeon at the John Radcliffe Hospital in Oxford where he obtained a Ph.D. (from Strathclyde) for studies of the inflammatory response during cardiac surgery. In 2004 he was appointed Professor of Cardiovascular Surgery at the University of Oxford.
His main interests are coronary revascularization, arterial grafts and off pump surgery. He has authored over 150 peer reviewed scientific papers and is the PI of the ART trial- one of the largest surgical trials ever conducted (a randomized trial of 3000 CABG patients to single or bilateral IMA grafts during CABG).
He was President of the Society for Cardiothoracic Surgery of GB and Ireland (April 2010-April 2012), Chairman of the European Society of Cardiology Cardiovascular Surgery Working Group, a member of the Adult Domain of the European Association for Cardiothoracic Surgery and a member of the AATS and STS. He was recently appointed as the lead for cardiothoracic Surgery in the U.K. by the Royal college of Surgeons of England.
Dr. Hemant Thatte is currently Associate Professor of Surgery at Harvard Medical School and Brigham and Women’s Hospital, and Director of Cardiac Surgery Research at the VA Boston Healthcare System. He has a doctorate from the University of Minnesota, and post-doctoral training, in Medicine from Stanford University School of Medicine, and in Biological Chemistry and Molecular Pharmacology, and Medicine from Harvard Medical School and Brigham and Women’s Hospital in Boston. His research laboratory is located at the West Roxbury campus of VA Boston Healthcare System.
His recent work is primarily focused on translational research in cardiac surgery, including but not limited to, evaluation of techniques of endoscopic surgical conduit harvest and development of new solutions for long-term preservation of bypass conduits use in cardiac and peripheral vascular surgery; design and development of an ex vivo perfusion system to physiologically maintain the surgical conduits by facilitating physiological distension, and flow induced prevention of apoptosis; reversal of acidosis induced apoptosis during cardiac surgery, to improve short and long-term patient outcomes; design novel technology for long-term preservation, resuscitation, maintenance and transport of heart and other organs for transplant. Dr. Thatte is the inventor of GALA, SOMAH, AMRUT and AAYUSOL solution technologies for the preservation of vascular surgical conduits used in bypass, organs for transplant, and RBC and Platelets for lesion-free banking and transfusion. GALA and SOMAH technologies have been licensed to Somahlution in Jupiter, Florida, by Harvard University and the Department of Veterans Affairs.
Dr. Thatte has published over 65 manuscripts in peer-reviewed journals. His contribution towards creating a new paradigm in heart transplant surgery by being able to store hearts in a fully functional state at ambient temperature was highlighted recently on the cover of American Journal of Transplant. Dr. Thatte has actively taught at Harvard Medical School for many years, and has been consistently rated as an outstanding teacher by the medical and dental students in their course evaluations. He has great passion for teaching, and has always strived for improvements in students and fellow’s academic excellence, development of their personality traits and leadership qualities; encouraging them to live extraordinary lives through their contributions.